Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularTOPICALGeneric

CANDEX

NYSTATIN

Standard Dose
100,000 UNITS/ML
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Summary

Approval overview CANDEX is listed in Drugs@FDA under application 050233 (NDA).

Marketing status: Discontinued Active ingredient NYSTATIN Form and strength LOTION;TOPICAL - 100,000 UNITS/ML Sponsor BAYER PHARMS Submission history See approval history documents.

Structured Monograph

Clinical summary

Approval overview CANDEX is listed in Drugs@FDA under application 050233 (NDA). Marketing status: Discontinued Active ingredient NYSTATIN Form and strength LOTION;TOPICAL - 100,000 UNITS/ML Sponsor BAYER PHARMS Submission history See approval history documents.

Monitoring

  • • Marketing status: Discontinued

Interaction Notes

  • No interaction notes stored yet.